Lilly’s Mirror Portfolio, a concept created to access exterior innovation, has acquired two molecules through an independent venture capitalist firm participating in the programme.
One molecule, developed pre-clinically by researchers at a major academic institution, is being studied as a potential treatment for congestive heart failure, while the second molecule is being studied for its potential in bone healing and cancer.
Through the Mirror Portfolio, companies financed by independent investments funds can acquire molecules, manage financing and determine various elements of research from one year before testing in humans to clinical proof-of-concept.
Molecules are then offered for sale to biopharmaceutical companies such as Lilly. In the case of a molecule being licensed from an academic institution, Chorus, Lilly’s virtual development organisation, will conduct studies under the companies’ discretion.